Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial.
Lancet HaematolSep 1, 2026
Clinical ResearchOncology (Medical)
Lorenzo Falchi, Joost S P Vermaat, Joshua D Brody et al.
✦ AI-curated · Sources linked
In 30 seconds
This open-label, phase 1b/2 trial evaluated the efficacy and safety of epcoritamab combined with rituximab and lenalidomide as first-line treatment for follicular lymphoma in 41 eligible patients. At a median follow-up of 35.9 months, the overall response rate was 95% (39 of 41 patients), indicating a promising treatment option.
Key findings
- The overall response rate was 95% (39 of 41 patients) at a median follow-up of 35.9 months.
- 49% of patients experienced grade 3-4 neutropenia.
- 71% of patients had serious adverse events, including cytokine release syndrome in 32%.
Why it matters
The high response rate observed with this chemotherapy-free regimen suggests a potential shift in treatment paradigms for follicular lymphoma, emphasizing the need for further investigation into its long-term efficacy and safety.